Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Genetics Generation AdvancementROCO:4160 +1.14%72 Debt-to-EBITDA is 2.38 as of Jun. 2026, which is 781% above its 10-year median of 0.27. GuruFocus rates ROCO:4160 with a GF Score™ of 72/100 and a GF Value™ of NT$53.25 (Modestly Undervalued). The stock has 8 warning signs investors should review. Among 112 Medical Diagnostics & Research companies, Genetics Generation Advancement ranks worse than 52.68% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Genetics Generation Advancement's Debt-to-EBITDA or its related term are showing as below:
ROCO:4160'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -2.24 Med: 0.27 Max: 2.43
Current: 2.43
During the past 13 years, the highest Debt-to-EBITDA Ratio of Genetics Generation Advancement was 2.43. The lowest was -2.24. And the median was 0.27.
ROCO:4160's Debt-to-EBITDA is ranked worse than 52.68% of 112
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.26
vs ROCO:4160: 2.43
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Genetics Generation Advancement Debt-to-EBITDA Related Terms
Genetics Generation Advancement Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4160 vs TMO, DHR, IDXX: Debt-to-EBITDA Comparison
For the Diagnostics & Research subindustry, Genetics Generation Advancement's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genetics Generation Advancement Debt-to-EBITDA vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Genetics Generation Advancement's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Genetics Generation Advancement's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.
Genetics Generation Advancement (ROCO:4160) has a Debt-to-EBITDA of 2.38 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Genetics Generation Advancement. This is 781% above median its historical median of 0.27. According to the industry distribution chart, Genetics Generation Advancement ranks #59 out of 112 companies in the Medical Diagnostics & Research industry, placing it in the top 52.7%.
Is Genetics Generation Advancement's Debt-to-EBITDA too high?
Genetics Generation Advancement's current Debt-to-EBITDA of 2.38 is 781% above median its 10-year median of 0.27. The Medical Diagnostics & Research industry median Debt-to-EBITDA is 2.26. Genetics Generation Advancement's value of 2.38 is 5.3% above this industry median. Based on the distribution chart, Genetics Generation Advancement ranks #59 out of 112 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Genetics Generation Advancement has a GF Score™ of 72/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genetics Generation Advancement's Debt-to-EBITDA compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Genetics Generation Advancement ranks #59 out of 112 companies for Debt-to-EBITDA. This places Genetics Generation Advancement in the lower half of its industry. The industry median Debt-to-EBITDA is 2.26. Genetics Generation Advancement's value of 2.38 is 5.3% above this benchmark. While the company's 10-year median is 0.27 vs. the industry median of 2.26, Genetics Generation Advancement has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Diagnostics & Research company?
The median Debt-to-EBITDA among Medical Diagnostics & Research companies is 2.26, based on 112 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Genetics Generation Advancement's current Debt-to-EBITDA of 2.38 is 5.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Genetics Generation Advancement. For the Medical Diagnostics & Research industry, the median Debt-to-EBITDA is 2.26 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genetics Generation Advancement's current Debt-to-EBITDA is 2.38, which is 781% above median its own 10-year median of 0.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genetics Generation Advancement stock overvalued right now?
Based on GuruFocus' analysis, Genetics Generation Advancement (ROCO:4160) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$53.25, compared to a current price of NT$40.05 — trading 24.8% below its estimated fair value. The current Debt-to-EBITDA is 2.38, which is 781% above median its 10-year median of 0.27 and 5.3% above the Medical Diagnostics & Research industry median of 2.26. Genetics Generation Advancement's overall GF Score™ is 72/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Genetics Generation Advancement (ROCO:4160), the current Debt-to-EBITDA is 2.38 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genetics Generation Advancement (ROCO:4160) Overvalued in 2026?
Based on GuruFocus' analysis, Genetics Generation Advancement stock appears to be undervalued.
The current stock price of NT$40.05 is trading 24.8% below its estimated GF Value™ of NT$53.25.
GuruFocus considers Genetics Generation Advancement to be Modestly Undervalued.
Key valuation signals for ROCO:4160:
Debt-to-EBITDA: 2.38 (781% above median its 10-year median of 0.27)
GF Value™: NT$53.25 vs. price of NT$40.05 (24.8% below fair value)
Industry Position: 5.3% above the Medical Diagnostics & Research median (#59 of 112)
No single metric tells the full story. See the ROCO:4160 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genetics Generation Advancement Corp is a Taiwan based company specialized in genetic testing and scientific information. It is engaged in providing services for the detection of genetic defects and prevention in newborns. Their main services include amniotic fluid chromosome chip screening, pre-implantation genetic diagnosis, and Molecular DNA testing diagnostics. The company is focused on the majority of areas of maternal precision medicine, pediatric disease diagnosis, drug-associated diagnosis, non-invasive cancer detection, and precise health management. The business units of the company are the Genetic Testing Unit and Informatics business unit.
72GF Score
Get the complete analysis for ROCO:4160
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4160 has been successfully added to your 
